Published in Am Heart J on September 01, 2009
Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov (2012) 1.75
Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol (2011) 1.12
Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proc Natl Acad Sci U S A (2010) 1.05
Proteinase-activated receptor-1, CCL2, and CCL7 regulate acute neutrophilic lung inflammation. Am J Respir Cell Mol Biol (2014) 0.95
Efficacy and safety of vorapaxar for the prevention of adverse cardiac events in patients with coronary artery disease: a meta-analysis. Cardiovasc Diagn Ther (2016) 0.89
Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol (2010) 0.89
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Health Risk Manag (2012) 0.88
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol (2012) 0.86
Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. Wien Med Wochenschr (2010) 0.84
Emerging antiplatelet agents, differential pharmacology, and clinical utility. J Blood Med (2010) 0.83
Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. Eur J Clin Pharmacol (2012) 0.81
Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice. Br J Pharmacol (2012) 0.80
Antiplatelet therapy: thrombin receptor antagonists. Br J Clin Pharmacol (2011) 0.78
Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc (2015) 0.78
Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. J Am Heart Assoc (2014) 0.77
Vorapaxar: targeting a novel antiplatelet pathway. P T (2011) 0.77
Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. Ann Med (2011) 0.76
Latest drug developments in the field of cardiovascular disease. Int J Angiol (2010) 0.75
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. J Am Heart Assoc (2015) 0.75
Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar. Drug Des Devel Ther (2015) 0.75
Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets. Mol Pharmacol (2016) 0.75
Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease. Drugs R D (2017) 0.75